Skip to main navigation
Skip to search
Skip to main content
University of Copenhagen Research Portal Home
Help & FAQ
Dansk
English
Home
Profiles
Research output
Research units
Press/Media
Activities
Prizes
???studenttheses???
Datasets
Search by expertise, name or affiliation
A comparative review of DPP-4 inhibitors and sulphonylureas
Carolyn F. Deacon
, HE Lebovitz
Endocrinology and Metabolism
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'A comparative review of DPP-4 inhibitors and sulphonylureas'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Nursing and Health Professions
Dipeptidyl Peptidase IV Inhibitor
100%
Sulfonylurea
100%
Side Effect
100%
Hypoglycemia
100%
Metformin
100%
Cardiovascular Risk
50%
Drug Therapy
50%
Diseases
50%
Non Insulin Dependent Diabetes Mellitus
50%
Monotherapy
50%
Oral Antidiabetic Agent
50%
Pharmacology, Toxicology and Pharmaceutical Science
Hypoglycemia
100%
Sulfonylurea
100%
Dipeptidyl Peptidase IV Inhibitor
100%
Side Effect
100%
Metformin
100%
Cardiovascular Risk
50%
Diseases
50%
Non Insulin Dependent Diabetes Mellitus
50%
Monotherapy
50%
Oral Antidiabetic Agent
50%
Pharmacotherapy
50%
Medicine and Dentistry
Sulfonylurea
100%
Dipeptidyl Peptidase-4 Inhibitor
100%
Glycemic Control
100%
Hypoglycemia
66%
Side Effect
66%
Type 2 Diabetes
66%
Glycon
66%
Drug Therapy
33%
Maturity Onset Diabetes of the Young
33%
Progressive Disease
33%
Monotherapy
33%
Oral Antidiabetic Agent
33%
Cardiovascular Risk
33%
Keyphrases
Sulfonylurea
100%
Dipeptidyl peptidase-4 (DPP-4)
100%
Glycemic Control
50%
Type 2 Diabetes Mellitus (T2DM)
33%
Weight Gain
33%
Pharmacotherapy
16%
Hypoglycemia Risk
16%
Safety Trial
16%
Hypoglycemia
16%
Oral Antidiabetic Drugs
16%
Adverse Effects
16%
Progressive Disease
16%
Treatment Algorithm
16%
Metformin Monotherapy
16%
Drug Class
16%
Cardiovascular Risk
16%
Metformin
16%